Press release
Pancreatic Cancer Market to Reach USD 11.2 Billion by 2034
Pancreatic Cancer
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70831
Market Overview - Key Highlights
• Market Size (2024): USD 5.6 billion
• Forecasted Market Size (2034): USD 11.2 billion
• CAGR (2024-2034): 7.2%
• Key Growth Drivers: Biomarker-driven therapy adoption, expansion of clinical trials, government and NGO-led screening initiatives.
• Challenges: Late diagnosis, high treatment costs, limited curative options.
• Top Players: F. Hoffmann-La Roche, Celgene (Bristol Myers Squibb), AstraZeneca, Novartis, Pfizer, Merck & Co., Ipsen, Eli Lilly, Amgen, Servier.
Segmentation Analysis
By Therapy Type
• Chemotherapy
o FOLFIRINOX
o Gemcitabine-based combinations
• Targeted Therapy
o PARP inhibitors (e.g., Olaparib)
o EGFR inhibitors (e.g., Erlotinib)
o KRAS G12C inhibitors (in trials)
• Immunotherapy
o Immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors)
o Cancer vaccines
• Radiation Therapy
• Surgery & Ablation
By Cancer Type
• Exocrine Pancreatic Cancer (Adenocarcinoma)
• Neuroendocrine Tumors (NETs)
By Biomarker Status
• BRCA1/2 or PALB2 Mutations
• Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR)
• KRAS Mutations
• Wild-Type
By End User
• Hospitals & Cancer Centers
• Specialty Clinics
• Academic & Research Institutes
By Region
• North America
• Europe
• Asia-Pacific
• Middle East & Africa
• Latin America
Segmentation Summary:
Chemotherapy continues to dominate first-line treatment, but targeted therapies-particularly for BRCA-mutated and MSI-H/dMMR tumors-are expanding rapidly. KRAS-targeted therapies in late-stage trials could significantly alter treatment algorithms by the end of the decade.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70831/pancreatic-cancer-market
Regional Analysis
North America
North America leads the market due to advanced diagnostic infrastructure, high participation in clinical trials, and early adoption of targeted therapies. The U.S. remains the global hub for pancreatic cancer research, with a large network of NCI-designated cancer centers.
Europe
Europe ranks second, with Germany, the UK, and France as key markets. Strong national health systems and inclusion of precision therapies in treatment guidelines contribute to growth, although access varies between Western and Eastern Europe.
Asia-Pacific
Asia-Pacific is the fastest-growing market, fueled by rising incidence, expanding cancer care infrastructure, and government screening programs in countries like Japan and South Korea. China's market is expanding rapidly due to a growing middle class and increased funding for oncology research.
Middle East & Africa
The market here is gradually expanding, led by GCC nations with significant investment in oncology centers. However, limited access to advanced therapies remains a barrier in much of Africa.
Latin America
Brazil and Mexico lead the region, with expanding oncology infrastructure and participation in global clinical trials. Affordability and access challenges persist, especially for targeted agents.
Regional Summary:
North America and Europe dominate in innovation and adoption, while Asia-Pacific's rapid expansion will drive global volume growth through 2034.
Market Dynamics
Key Growth Drivers
1. Increased Genetic Testing: Wider adoption of germline and somatic testing for actionable mutations.
2. Breakthrough Therapies: Approvals of PARP inhibitors and immune checkpoint inhibitors for select biomarker-positive patients.
3. Screening in High-Risk Populations: Targeted screening for individuals with familial pancreatic cancer or genetic predispositions.
4. Combination Approaches: Trials combining chemotherapy, targeted therapy, and immunotherapy to improve response rates.
Key Challenges
1. Late Diagnosis: Over 80% of cases are diagnosed at advanced stages.
2. Drug Resistance: Limited durability of response with current therapies.
3. High Treatment Costs: Targeted therapies and immunotherapies remain expensive.
4. Low Survival Rates: Five-year survival remains under 12% globally.
Latest Trends
1. KRAS-targeted Drug Development: Novel inhibitors addressing the most common mutation in pancreatic cancer.
2. Cancer Vaccines & Cellular Therapies: Experimental approaches aiming to boost immune response.
3. Liquid Biopsy for Early Detection: Non-invasive methods for monitoring and diagnosis.
4. AI in Imaging: Machine learning for earlier and more accurate tumor detection.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70831
Competitor Analysis
Major Players:
• F. Hoffmann-La Roche Ltd.
• Celgene (Bristol Myers Squibb)
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc.
• Merck & Co., Inc.
• Ipsen
• Eli Lilly and Company
• Amgen Inc.
• Servier
• BeiGene
• Mirati Therapeutics (now part of Bristol Myers Squibb)
• Guardant Health (diagnostics)
• Foundation Medicine (companion diagnostics)
• Exelixis, Inc.
Competitive Landscape Summary:
The market is moderately consolidated, with leading companies holding strong positions in chemotherapy and targeted therapy segments. Strategic partnerships between drug developers and diagnostics companies are becoming increasingly important for companion diagnostics integration.
Conclusion
The pancreatic cancer market is poised for strong growth over the next decade, driven by precision medicine, expanding biomarker testing, and novel drug approvals. While late diagnosis remains a critical challenge, targeted therapies and combination regimens are improving patient outcomes in biomarker-defined subgroups.
Key Takeaways:
• Market projected to grow at 7.2% CAGR from 2024 to 2034.
• Targeted therapy and immunotherapy adoption will accelerate as testing rates increase.
• Asia-Pacific offers the highest growth potential, while North America leads innovation.
• Liquid biopsy, KRAS inhibitors, and AI-driven diagnostics are key trends shaping the next decade.
The future of pancreatic cancer treatment lies in early detection, personalized therapy, and integrated care pathways, potentially transforming survival outcomes for one of the deadliest cancers.
This report is also available in the following languages : Japanese (膵臓がん市場), Korean (췌장암 시장), Chinese (胰腺癌市场), French (Marché du cancer du pancréas), German (Markt für Bauchspeicheldrüsenkrebs), and Italian (Mercato del cancro al pancreas), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @https://exactitudeconsultancy.com/reports/70831/pancreatic-cancer-market#request-a-sample
Our More Reports:
Inflammation and Pain Post Cataract Surgery Market
https://exactitudeconsultancy.com/reports/70915/inflammation-and-pain-post-cataract-surgery-market
Non-Postoperative Acute Pain Market
https://exactitudeconsultancy.com/reports/70917/non-postoperative-acute-pain-market
Postoperative Acute Pain Market
https://exactitudeconsultancy.com/reports/70919/postoperative-acute-pain-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Market to Reach USD 11.2 Billion by 2034 here
News-ID: 4143770 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
